| Autor: |
Batran, Radwa Ahmed, Elmoshneb, Mai, Hussein, Ahmed Salah, Hussien, Omar M, Adel, Fady, Elgarhy, Reham, Morsi, Mosaad I |
| Předmět: |
|
| Zdroj: |
Biologics: Targets & Therapy; Oct2022, Vol. 16, p161-171, 11p |
| Abstrakt: |
Biosimilars are biological products that efficiently replicate the function of the originator products. They have changed the prognosis of millions of patients with many serious conditions. The main engine beyond their development is to bring competition into the marketplace, accordingly further the healthcare systems' sustainability. Furthermore, by lowering financial obstacles to biological treatments, biosimilars play a critical role in budgetary redistribution and, hence, promote better allocation of scarce healthcare resources. Today, biosimilars have become a substantial component of effective biological therapies anywhere in the world. Alike, most Middle East and African countries are encouraging the domestic biosimilars industry, and the whole region is aware of the biosimilars' importance. However, constraints to increasing biosimilars uptake should be addressed. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
